

NIH HEAL INITIATIVE

March 1-2, 2022

Multi-Disciplinary Working Group Spring Meeting






Helping to End Addiction Long-term Research Overview

Rebecca Baker, Director, NIH HEAL Initiative, Office of the Director, NIH

Crisis #1: National Overdose Deaths



Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods

21% increase in fatal drug overdoses in 12 months ending June 2021

Driven by powerful synthetic opioids like fentanyl and rising polysubstance use

10 Million Americans misuse opioids, at risk for OUD or overdose

54.4

Crisis #2: Pain in the United States

- 50 million adults affected by chronic pain
- 25 million report severe pain daily
- 20 million have high impact chronic pain
 - Risks associated with opioid medications
 - Challenges to high quality, multidisciplinary pain management



CDC, Morbidity and Mortality Weekly Report, Sept. 2018



The Response: NIH HEAL Initiative

- Over \$2 billion in research
- More than 600 research projects
- 26 research programs
- Projects underway in all 50 States
- Released 50+ funding announcements since inception
 - ₀ 30+ open now!!

From prevention research, basic and translational research, clinical trials, to implementation science






Preclinical and Translational Research in Pain Management

\$335M to date; non-addictive analgesic development programs

- Discovery and validation of novel targets for safe and effective pain treatment
 - 2 patents for small molecule modulators of pain receptorschronic pain and migraine
 - Investigational New Drug (IND) for a first-in-class nonadditive drug candidate for the treatment of chronic pain
- Screening and testing platforms, tissue chips, and optimization research
- Devices to treat pain
 - Portable thermoelectric device to inhibit pain signals in two different peripheral nerves
- Team based research framework







Preclinical and Translational Research in Pain Management

\$335M to date; non-addictive therapeutic development programs

Launched in 2021:

 Expanded analgesic therapeutics development program- planning studies and phased awards

Planned for 2022:

- Devices for pain relief
- Studying pain in human genes & cells
- Restoring joint health and function (REJOIN)
- HEAL Innovator awards







Clinical Research in Pain Management

\$351M to date; supports research to evaluate and compare pain management approaches

- Early Phase Preclinical Investigation Network (EPPIC Net)
 - New treatment for pain from knee osteoarthritis and diabetic neuropathy
- Back Pain Consortium (BACPAC)
 - Iterative model precision medicine for chronic low back pain
- Hemodialysis Opioid Prescription Effort (HOPE)
 - Multidisciplinary pain management for people on kidney dialysis
- Pain Effectiveness Research Network (Pain ERN)
- Pragmatic and Implementation Studies for Management of Pain to reduce opioid prescribing (PRISM)
- Integrated Management of chronic pain and OUD (IMPOWR)





Clinical Research in Pain Management

\$351M to date; supports research to evaluate and compare pain management approaches

Launched in FY2021:

- Integrated management of chronic pain and OUD (IMPOWR) program
- Focus on health equity in pain management: interventions to mitigate effects of bias, stigma and socioeconomic barriers to pain treatment

Planned for FY2022:

- Quantitative imaging and biomarkers of myofascial tissues
- Enhancing the pain research workforce
- Secondary data analysis for acute and chronic pain





New Prevention & Treatment Strategies for Opioid Use Disorder

\$226M to date; develop new or improved prevention and treatment strategies

- Optimizing care for people with opioid use disorder and mental health conditions
- Preventing opioid use disorder in at-risk groups
 - Adolescents transitioning to adulthood, homeless, American Indian/Alaskan native (AI/AN)
- The role of sleep in opioid use disorder
- Tools for pharmacists to identify high risk opioid use patterns for early intervention





New Prevention & Treatment Strategies for Opioid Use Disorder

\$226M to date; develop new or improved prevention and treatment strategies

Pre-Clinical/ Translational Research in Pain Management ENHANCING PAIN MANAGEMENT IMPROVING TREATMENTS FOR OPIOID MISUSE AND ADDICTION Enhanced Outcomes For Affected Newborns If the Preventior of Treatment Strategies In the Preventior of Treatment Strategies In the Preventior of Treatment Strategies

Launched in 2021:

 Research to optimize multi-component service delivery interventions for OUD and mental health conditions

Planned for 2022:

- Management of polysubstance use through the NIDA Clinical Trials Network
- Screening for OUD
- Preventing opioid misuse by intervening on social determinants of health



Translation of Research into Practice for Effective Treatments for OUD

\$611M to date; suite of implementation science efforts

- Behavioral Research to Enhance Medication-Based Treatment of OUD
- HEALing Communities Study
 - Communications campaign for community uptake of medications for OUD and naloxone
 - Real-time data tools to monitor overdose spikes
- Justice Community Opioid Innovation Network
 - Emerging best practices for criminal justice agencies on addressing OUD in the context of COVID-19



Translation of Research into Practice for Effective Treatments for OUD

\$611M to date; suite of implementation science efforts

Planned for 2022:

- Recovery support services research
- Harm reduction strategies, including use of fentanyl test strips, in HCS
- Real-world application of existing data through *Data 2 Action*
 - Includes support centers for infrastructure, research adoption, and economic modeling






Novel Therapeutic Options for Opioid Use Disorder and Overdose:

\$363M to date; expand treatment options for all aspects of the opioid addiction cycle

- 50+ compounds being developed from early preclinical to late clinical phases
- 20 INDs filed with FDA
 - Exceeding HEAL Initiative goal of 15 INDs in 5 years
- Biologics: First study in humans of an opioid vaccine
- Devices: One IDE for Deep Brain Stimulation as a treatment for OUD





Novel Therapeutic Options for Opioid Use Disorder and Overdose:

\$363M to date; expand treatment options for all aspects of the opioid addiction cycle

Launched in 2021:


 Medications development for stimulant use disorder and polysubstance use

Planned for 2022:

- Novel targets for OUD and overdose
- Pharmacotherapies to reverse opioid induced respiratory depression without central opioid withdrawal
- Novel digital therapeutics for OUD



HOW THE OPIOID VACCINE WORKS



Enhanced Outcomes for Infants and Children

\$83M to date; addressing the long-term consequences of early opioid exposure

- Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW)
 - 2 clinical trials –weaning and eat-sleep-console,
 - 1 longitudinal study
 - Early survey found significant site to site practice variation in treatment of infants with NOWS;
- HEALthy Brain and Child Development Study (HBCD)
 - Longitudinal study enrolling pregnant women across the US
 - Developing neuroimaging measures in infants and young children





Enhanced Outcomes for Infants and Children

\$83M to date; addressing the long-term consequences of early opioid exposure

Launched in 2021:

- Healthy Brain and Child Development Study
 - Consultation with NIH Bioethics Office--seeking an external bioethics consult
- ACT NOW comparative-effectiveness trial
 - Goal to determine appropriate pharmacological treatment of infants with NOWS

Planned for 2022:

Peer specialist support for HEAL studies





Cross Cutting Themes

- Integrating pain and OUD research
- Health equity research, enhanced participant diversity
- Partnership with people with lived experience
- Research dissemination and the HEAL Data Ecosystem
- Adapting Research Interventions for COVID-19
- And much more...

Viewpoint

ONLINE FIRST FREE

August 26, 2021

The Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health

Rebecca G. Baker, PhD¹; Walter J. Koroshetz, MD²; Nora D. Volkow, MD³

» Author Affiliations | Article Information

JAMA. Published online August 26, 2021. doi:10.1001/jama.2021.13300



NIH HEAL INITIATIVE



he Helping to End Addiction Long-term (HEAL) initiative of in 2018 to provide scientific solutions to the evolving crisi dedicated support from Congress, the HEAL initiative has funded than 500 projects nationwide, and plans to expand research inverse fforts to develop more effective therapies for managing pain a fective pain management strategies that limit addiction risk, and variety of settings. The HEAL initiative joins the power of scient an urgent public health need (see Table for selected research as







2022 HEAL Annual Report coming soon!





HEAL Current Activities and Future Directions

HEAL Budget: FY2022 and FY2023 Look-ahead

- President FY2022 budget proposed extra \$270M for HEAL research
 - Part of \$627M proposed increase in pain, opioid research across NIH, including increases directed to individual Institutes and Centers
- NIH considering plans in case budget increase becomes a reality
- Plan for similar fiscal level in FY2023



New Research Directions for HEAL Research in 2022 align with HHS Overdose Prevention Strategy

Care Coordination and Collaboration

- Pain Management in Systems of Care
- Research Adoption Partnerships
- Multicomponent Care for Mental Health, OUD and comorbidities

Health Equity

- Sickle Cell Disease Pain Management
- Social Determinants of Addiction and Behavioral Health
- Advancing Health Equity in Pain

Data Driven Research

- Real World Healthcare Data
- Secondary Data Analysis
- Data2Action Partnerships

Harm Reduction

 Policies, Practices and Modes of Delivery for Harm Reduction

Evidence Based Treatments

- Polysubstance Use
- Medication Development
- Recovery Support Services

Preventing Overdose Through Pain Management

- New Targets and Candidate Therapeutics for Pain
- Novel Pain Treatments
- Training and Innovator Awards

New Research Directions for HEAL in FY2023

Improve Care through Coordination, Collaboration

- Pain Management in Rural communities
- Multilevel Interventions for Patients on Long-term Opioid Therapy

Health Equity

- Medications for OUD in diverse groups
- Social Determinants of Addiction and Behavioral Health

Data Driven Research

- Longitudinal Tracking of Opioid Exposures and Health Outcomes
- Piloting the HEAL Data Ecosystem

Evidence Based Treatments

- Addressing Polysubstance Use
- Medication Development

Preventing Overdose Through Pain Management

- Integrated Basic and Clinical Research
- High-throughput Tech
- Innovative Devices to Treat Pain

Thanks! HEAL Scientific Teams and Leadership



Ivan Montoya, NIDA



Alex Talkovsky, NIMH



Jane Atkinson, NCATS

Scientific team membership of 200+ program staff representing 20+ ICOs across NIH



Kentner Singleton, NIAID



Geetha Subramaniam, NIDA



Linda Porter, NINDS



Wendy Weber, NCCIH



Christine Colvis, NCATS



Drew Bremer, NICHD



Chicago and
sures and sures and sures are sures as an and attent to the district to the distri

Tisha Wiley, NIDA



Michael Oshinsky, NINDS



Michelle Freund, NIDA

Thanks! NIH Executive Committee



Lawrence Tabak, NIH Acting Director



Tara Schwetz,Acting Principal
Deputy Director



Walter Koroshetz, NINDS Director



Nora Volkow, NIDA Director



Diana Bianchi, NICHD Director



Rena D'Souza, NIDCR Director



Joshua Gordon, NIMH Director



Helene Langevin, NCCIH Director



Joni Rutter, NCATS Acting Director



Shannon Zenk, NINR Director



Lindsey Criswell, NIAMS Director

Thank You! Questions?